CLIMB BIO INC (CLYM)
Health Care · Clinical-stage immunology / monoclonal antibody therapeutics · NASDAQ
Clinical-stage biotech developing budoprutug, an anti-CD19 monoclonal antibody for B-cell depletion in autoimmune diseases including membranous nephropathy and lupus.
What CLIMB BIO INC does
Climb Bio is a clinical-stage biotechnology company developing therapeutic candidates for immune-mediated diseases, with a focus on B-cell depletion strategies. The company's lead product, budoprutug, is an anti-CD19 monoclonal antibody in Phase 2 clinical trials for primary membranous nephropathy and Phase 1b/2a trials for immune thrombocytopenia. The company also has CLYM116, another product candidate, with development rights worldwide outside Greater China.
Themes: ["Immunology / immune-mediated diseases","B-cell depletion","Monoclonal antibodies","Autoimmune disease treatment","Clinical-stage biotech"]
Fundamentals
- Price$13.82 as of 2026-07-09 close
- Market cap$791M as of 2026-07-10
- 1-year return+977.0% as of 2026-07-09 close
- ROE-31.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.10 as of 2026-07-10
Key risks (from latest filing)
["Clinical-stage company with no approved products or revenue; dependent on successful completion of Phase 2/Phase 1b trials for budoprutug in pMN, ITP, and SLE with uncertain regulatory approval outcomes","Significant ongoing losses with no current product revenue; substantial capital requirements to complete development and commercialization, with future financing needs and related dilution risks","Competitive landscape includes established players with approved B-cell targeting therapies and monoclonal antibodies; budoprutug must demonstrate superior efficacy, safety, or durability to gain market acceptance"]
Competitors & peers
- Biogen (BIIB)
- Horizon Therapeutics (HZNP)
- Amgen (AMGN)
- Eli Lilly (LLY)
- Roche (RHHBY)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.